NCI NRG-BN007

Brain Glioblastoma (GBM) - NCI NRG-BN007

NCI NRG-BN007

Objective

A RANDOMIZED PHASE II/III OPEN-LABEL STUDY OF IPILIMUMAB AND NIVOLUMAB VERSUS TEMOZOLOMIDE IN PATIENTS WITH NEWLY DIAGNOSED MGMT (TUMOR O-6-METHYLGUANINE DNA METHYLTRANSFERASE) UNMETHYLATED GLIOBLASTOMA

Principal Investigator(s)
Andrew Horodner, MD
Jeremy Rudnick, MD

Clinical Trial Categories

  • Cedars-Sinai Clinical Trials